Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation.

Trial Profile

Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Acenocoumarol; Enoxaparin sodium; Warfarin
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Registrational; Therapeutic Use
  • Acronyms EINSTEIN-PE
  • Sponsors Bayer
  • Most Recent Events

    • 29 Oct 2015 Results (n=8245) of this and EINSTEIN-DVT trial published in the Thrombosis and Haemostasis
    • 31 Mar 2014 Pooled sub-study results for the influence of prestudy heparin from the EINSTEIN DVT and EINSTEIN PE trails presented at the 63rd Annual Scientific Session of the American College of Cardiology.
    • 10 Dec 2012 Results reporting duration of hospitalisation presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top